| CAS NO: | 2095515-38-9 |
| 包装 | 价格(元) |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Cas No. | 2095515-38-9 |
| Canonical SMILES | N#CC1=CC=C2N(C)C([C@@H](N3CCC4=C(Cl)N(CC5=CC=CC=C5)N=C4C3=O)COC2=C1)=O |
| 分子式 | C24H20ClN5O3 |
| 分子量 | 461.9 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | 4°C, away from moisture and light |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | RIP1 kinase inhibitor 1 (compound 22) is a highly potent, orally available, and brain-penetrating RIP1 kinase inhibitor (pKi=9.04)[1]. pKi: 9.04 (RIP1 kinase)[1] RIP1 kinase inhibitor 1 (compound 22) strongly suppresses necroptotic cell death and phosphorylation of MLKL(pMLKL) in human colorectal adenocarcinoma HT-29 cells (nectoptosis, IC50=2 nM; pMLKL, IC50=1.3 nM) as well as mouse L-cells NCTC 929 (nectoptosis, IC50=15 nM; pMLKL, IC50=2.7 nM)[1]. [1]. Yoshikawa M, et al. Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine Derivatives as Potent, OrallyAvailable, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships. J Med Chem. 2018 Mar 22;61(6):2384-2409. |
m.cnreagent.com